A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate 2 Different Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2015
At a glance
- Drugs Romosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 07 Jun 2017 Biomarkers information updated
- 14 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Apr 2014 Planned End Date changed from 1 Feb 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.